| The John Hopkins University Patent applications |
| Patent application number | Title | Published |
|---|
| 20120115804 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING NEOPLASIA - The invention features compositions and methods for characterizing the methylation status of the Vitamin D Receptor (VDR) in neoplasia (e.g., breast carcinoma), selecting an appropriate therapy, and treating the neoplasia (e.g., breast carcinoma). | 05-10-2012 |
| 20120107927 | METHODS AND DEVICES FOR ISOLATING EMBRYONIC STEM CELLS - Methods, devices and kits are provided for isolating or enriching multicellular embryonic stem (ES) cell colonies from a mixture of multicellular ES cell colonies and single ES cells present in a cellular suspension, by utilizing a filtration matrix that selectively excludes passage of multicellular ES cell colonies. Isolated or enriched multicellular ES cell colonies can be used for propagating pluripotent ES cells. | 05-03-2012 |
| 20120093821 | PAPILLOMAVIRUS-LIKE PARTICLES (VLP) AS BROAD SPECTRUM HUMAN PAPILLOMAVIRUS (HPV) VACCINES - This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or HPV) L1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus L2 protein. Vaccine compositions comprising the VLP are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the VLP, and kits comprising the VLP, for carrying out a method of the invention. | 04-19-2012 |
| 20120059399 | BIOLOGICAL TISSUE CONNECTION AND REPAIR DEVICES AND METHODS OF USING SAME - The instant invention provides compositions and methods for promoting the repair and/or growth of biological tissue, e.g., tubular biological tissue such as nerves. Specifically, the instant invention provides tissue connection devices and tissue repair devices and methods for using these devices. | 03-08-2012 |
| 20110245772 | FOCAL CALCIUM CHANNEL MODULATION - Disclosed is an invention for focally modulating the activity of a calcium channel in a mammal. In one aspect, the invention features a method that includes contacting a pre-determined tissue or organ region with a nucleic acid sequence encoding a GEM protein or a variant thereof to express the GEM protein or variant within the region. Typical methods further include expressing the GEM protein or variant so as to modulate the activity of the calcium channel. The invention has a wide spectrum of useful applications including treating a medical condition associated with unsuitable calcium channel activity. | 10-06-2011 |
| 20110245751 | METHODS AND DEVICES FOR PERCUTANEOUS AND SURGICAL INTERVENTIONS - Methods and devices for performing percutaneous and surgical interventions. The devices comprising a tubular portion and retractable mechanism at the distal end of the tubular portion. The retractable mechanism prevents the device from pulling out of an anatomical structure during complex interventions, for example, when switching from an antegrade to a retrograde approach within a blood vessel, enables the use of a single sheath when declotting AV hemodialysis fistulas and can provide occlusion of blood flow during interventions and means of removal of debris or clot from the blood vessel. | 10-06-2011 |
| 20110218220 | RATIONALLY IMPROVED ISONIAZID AND ETHIONAMIDE DERIVATIVES AND ACTIVITY THROUGH SELECTIVE ISOTOPIC SUBSTITUTION - The present invention relates to the use of isotopically labeled derivatives of isoniazid, ethionamide and related compounds as effective therapy for the treatment of mycobacterial diseases, including | 09-08-2011 |
| 20110200987 | COMPOSITIONS AND METHODS FOR MODIFYING CELLULAR PROPERTIES - The invention generally provides compositions and methods for modulating cell properties and enhancing recombinant protein yields. In particular, the compositions and methods provide for cells having altered growth characteristics, including altered adhesion, rate of proliferation, growth to particular cell density, and recombinant protein expression level. | 08-18-2011 |
| 20110104146 | ANTITHROMBOTIC AGENTS AND METHODS OF USE THEREOF - The instant invention provides methods and compositions for the treatment, prevention and diagnosis of for example, platelet aggregation or clot formation in a subject. The invention inhibits the activity of decreases the amount of neutrophils in the subject by inhibiting the activity or production of IL-6, interferon-gamma, STAT1, or cathepsin D. The invention addresses decreasing the amount of neutrophils in an attempt to treat subjects that have or are at risk of developing a vascular occlusive disease, an ischemia or reperfusion injury, an acute or chronic inflammatory state, autoimmune disease, myelodysplastic syndrome, tissue injury from surgery or accidental trauma, acute bacterial or viral infection, has undergone a microvascular surgical reconstructive procedure, is receiving granulocyte colony stimulating factor therapy, receiving stem cell therapy, or has sickle cell anemia. | 05-05-2011 |
| 20110059435 | Methods for Beaming - Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutations in DNA isolated from plasma of cancer patients. | 03-10-2011 |
| 20110024727 | LOW-VOLTAGE, N-CHANNEL HYBRID TRANSISTORS - Hybrid semiconducting-dielectric materials and electronic or electro-optic devices using the hybrid semiconducting-dielectric materials. Hybrid semiconducting-dielectric materials comprise molecules that have a core section that provides an n-type semiconducting property and side chains that provide a dielectric property to a layer of hybrid semiconducting-dielectric material. Specific hybrid semiconducting-dielectric materials include tetracarboxylic diimide compounds having sidechains comprising fluorine substituted aliphatic or aromatic moieties linked to the tetracarboxylic diimide structure by an alkylene or heteroalkylene linking group. | 02-03-2011 |
| 20110008888 | Novel Genetic Approaches to Reduce or Inhibit Tumorgenicity of Human Embryonic Stem Cells and Derivatives Following Transplantation - Self-renewable embryonic stem cells (ESCs), derived from the inner cell mass of blastocysts, can propagate indefinitely in culture while maintaining their normal karyotypes and pluripotency to differentiate into all cell types. Therefore, ESCs may provide an unlimited supply of even specialized cells such as brain and heart cells for transplantation and cell-based therapies that are otherwise limited by donor availability. However, this promising application is hampered by concerns that ESCs or their multipotent derivatives also possess the potential to form malignant tumors after transplantation in vivo. The present invention provides for a novel genetic method to arrest undesirable cell division (of ESCs and other unwanted lineages) as a means to inhibit or eliminate their tumorgenic potential after transplantation. | 01-13-2011 |
| 20100326071 | RECONFIGURABLE LITHOGRAPHIC STRUCTURES - A lithographically structured device has an actuation layer and a control layer operatively connected to the actuation layer. The actuation layer includes a stress layer and a neutral layer that is constructed of materials and with a structure such that it stores torsional energy upon being constructed. The control layer is constructed to maintain the actuation layer substantially in a first configuration in a local environmental condition and is responsive to a change in the local environmental condition such that it permits a release of stored torsional energy to cause a change in a structural configuration of the lithographically structured device to a second configuration, the control layer thereby providing a trigger mechanism. The lithographically structured device has a maximum dimension that is less than about 10 mm when it is in the second configuration. | 12-30-2010 |
| 20100303881 | Therapeutic Electrospun Fiber Compositions - The instant invention provides electrospun fiber compositions comprising one or more polymers and one or more biologically active agents. In specific embodiments, the biologically active agents are nerve growth factors. In certain embodiments, the electrospun fiber compositions comprising one or more biologically active agents are on the surface of a film, or a tube. The tubes comprising the electrospun fiber compositions of the invention can be used, for example, as nerve guide conduits. | 12-02-2010 |
| 20100297144 | MULTITYPE HPV PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF HUMAN PAPILLOMAVIRUS INFECTION - Embodiments of the invention are directed to methods and compositions of multitype HPV polypeptides. | 11-25-2010 |
| 20100267576 | Compositions And Methods For Identifying And Treating Subjects At Risk Of Developing Type 2 Diabetes - Disclosed herein are compositions and methods for the identification of a subject at risk for developing type 2 diabetes. Also disclosed is a therapeutic target for the prevention and treatment of type 2 diabetes. | 10-21-2010 |
| 20100056900 | APPARATUS FOR INSERTION OF A MEDICAL DEVICE WITHIN A BODY DURING A MEDICAL IMAGING PROCESS AND DEVICES AND METHODS RELATED THERETO - A device, system, and method for entering a medical device such as a needle into the body inside a medical imager such as a MRI scanner, CT, X-ray fluoroscopy, and ultrasound imaging, from within a body cavity (such as the rectum, vagina, or laparoscopically accessed cavity). A three degree-of-freedom mechanical device translates and rotates inside the cavity and enters a needle into the body, and steers the needle to a target point selected by the user. The device is guided by real-time images from the medical imager. Networked computers process the medical images and enable the clinician to control the motion of the mechanical device that is operated within the imager, outside of the imager or remotely from outside the imager. | 03-04-2010 |
| 20100047812 | PEPTIDE ANTIBODY DEPLETION AND ITS APPLICATION TO MASS SPECTROMETRY SAMPLE PREPARATION - The present invention relates, e.g., to a method for pre-processing a sample for mass spectral analysis, comprising cleaving proteins in the sample to peptides and immunodepleting highly abundant and/or well-ionizing and/or proteotypic peptides from the sample. Also described are methods for identifying well-ionizing peptides for use in this and other methods: analytic (diagnostic) methods using antibodies against highly ionizable peptides from a protein target of interest; and compositions kits and devices comprising antibodies of the invention. | 02-25-2010 |
| 20100034793 | METHOD OF USING STROMA CELLS FROM CORD BLOOD TO EXPAND AND ENGRAFT NUCLEATED CELLS FROM CORD BLOOD - The invention features a method for expanding and engrafting nucleated cells, e.g., progenitor cells, such as hematopoietic cells, obtained from cord blood by co-culturing the nucleated cells with adherent stroma cells, e.g., mesenchymal stem/progenitor cells, also obtained from cord blood. | 02-11-2010 |
| 20090311226 | COMPOSITION AND METHOD FOR TREATING ESOPHAGEAL DYSPLASIA - Enhancing the immune response to esophageal tumor cells reduces the incidence of esophageal cancer developing, recurring, or metastasizing. Esophageal cancer cells are modified to render them more immunogenic and proliferation compromised. They are used in an antigenic preparation to raise a T cell response in the recipient. | 12-17-2009 |
| 20090298095 | Immortalization of cells including neuronal cells - The instant invention provides methods for immortalizing cells. The invention further provides immortalized cell lines, e.g., neuronal cell lines, and methods of using these cell lines in screening assays. | 12-03-2009 |
| 20090298065 | Methods for Identifying Functional Noncoding Sequences - The present invention relates to methods for identifying functional noncoding human sequences. Methods may comprise one or more of the following: a comparative genomic sequence analysis step, a genetic analysis step, and a functional analysis step. The functional analysis step comprises transposon-based transgenesis in zebrafish. Also disclosed here in a transposon-based vector to facilitate efficient transgenesis in zebrafish. | 12-03-2009 |
| 20090281067 | Nitroxyl progenitor compounds and methods of use - Described herein are nitroxyl progenitor compounds, and compositions including, and methods or generating, the compounds thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions. | 11-12-2009 |
| 20090214519 | Compositions and Methods for Treating Inflammation - The present invention relates to compositions to treat inflammation (LIGHT pathway) related disorders, and specifically liver inflammation or hepatitis. The invention also relates to methods treating LIGHT pathway related disorders. The invention further relates to kits for treating LIGHT pathway related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating LIGHT pathway related disorders in a subject. | 08-27-2009 |
| 20090074796 | Pde5 inhibitor compositions and methods for immunotherapy - The invention features methods and compositions featuring a PDE5 inhibitor for treating or preventing immunological-mediated disease in a subject. | 03-19-2009 |
| 20090054358 | Flt3 inhibitors for immune suppression - New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity. | 02-26-2009 |
| 20090046831 | BENCH-TOP IMAGE-GUIDED CONFORMAL IRRADIATION SYSTEM FOR LABORATORY ANIMALS - An image-guided irradiation system has a support stage, a stage-positioning assembly connected to the support stage, an x-ray source attached to a support arm in which the support arm is movable relative to the support stage, a flat-panel x-ray detector disposed proximate the support stage, and at least one of a collimator or an x-ray lens selectively disposable between the x-ray source and the support stage. The x-ray source is suitable to provide an imaging beam of X-rays at a first photon energy and is suitable to provide an irradiation beam of X-rays at a second photon energy. The collimator or x-ray lens is structured and arranged to define at least a width of the irradiation beam when it is disposed between the x-ray source and the support stage while the x-ray source is in operation. | 02-19-2009 |
| 20090017030 | Endothelial Cell Expression Patterns - To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future. | 01-15-2009 |
| 20090010844 | Imaging Infection With Compounds That Bind to Thymidine Kinase - The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection. | 01-08-2009 |
| 20080312326 | Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist - The present invention relates to the use of EP | 12-18-2008 |
| 20080262345 | Image registration of multiple medical imaging modalities using a multiple degree-of-freedom-encoded fiducial device - Disclosed is a system and method for registering images from two medical imaging modalities in a six-degree-of-freedom coordinate space, for the purpose of providing real time registered imagery for optimization of medical procedures. The system and method uses fiducial that is visible to the first imager and in a fixed position and orientation relative to the second imager. The first imager may be an X-ray device such as a C-arm fluoroscope, and the second imager may be a Transrectal Ultrasound (TRUS) device. | 10-23-2008 |
| 20080261909 | Gene Delivery to Organs - Application of a virus with poloxamer alone onto atria results in diffuse epicardial gene transfer with negligible penetration into the myocardium. Progressive increases in protease concentration, however, allow transmural gene transfer. After protease exposure, echocardiographic left atrial diameter does not change. Left atrial ejection fraction decreases on post-operative day 3, but returns to baseline by day 7. At appropriate protease concentrations, tissue tensile strength is unaffected by the procedure. Transmural atrial gene transfer can be effected using this direct “painting” method. | 10-23-2008 |
| 20080244760 | Transgenic Frog Lines and Assays Employing Them - Rhodopsin transgenes driven by rhodopsin promoters were produced, some attached to GFP coding sequences as a fusion construct. When the resulting transgenes were introduced into | 10-02-2008 |
